Form 4: Avidity Biosciences Director Levin Exercises Options and Sells Shares
SEC Form 4 Filing
Director Arthur A. Levin exercised stock options and sold shares of Avidity Biosciences (RNA) on October 21, 2024, according to a Form 4 filing.
Summary
- On October 21, 2024, Arthur A. Levin, a director of Avidity Biosciences, Inc., exercised options to purchase 5,000 shares of common stock at a price of $1.24 per share.
- Simultaneously, Levin sold 5,000 shares of Avidity Biosciences common stock at a weighted-average price of $46.6335, with individual sales prices ranging from $45.99 to $48.30.
- These transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on May 26, 2023.
- Following these transactions, Levin directly owns 14,830 shares of common stock and indirectly owns 131,372 shares through a family trust.
- Levin also continues to hold options for 3,323 shares.
Sentiment
Score: 5
Explanation: The sentiment is neutral. It's a routine disclosure of insider trading activity under a pre-arranged plan. There's no indication of unusual or concerning behavior.
Industry Context
This Form 4 filing is a routine disclosure of insider transactions. It provides transparency into the trading activities of company directors and officers, which is important for investors to assess management's confidence in the company's prospects. The use of a pre-arranged Rule 10b5-1 trading plan suggests that these transactions were planned in advance and not based on any material non-public information.
Comparison to Industry Standards
- Form 4 filings are standard practice for publicly traded companies and their insiders.
- The use of Rule 10b5-1 trading plans is a common method for corporate insiders to sell shares without raising concerns about insider trading.
- The reported price range for the share sale is within the typical market fluctuations for Avidity Biosciences' stock.
Stakeholder Impact
- The transactions may have a minor impact on shareholders due to the sale of shares by a director.
- The disclosure provides transparency to stakeholders regarding insider trading activities.
Key Dates
| Date | Description |
|---|---|
| 2023-05-26 | Date of adoption of Rule 10b5-1 trading plan. |
| 2024-10-21 | Date of stock option exercise and share sale. |
| 2024-10-23 | Date of signature on the Form 4 filing. |
| 2030-02-18 | Expiration date of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.